Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study.
about
Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trialPlasma proteomic analysis of stable coronary artery disease indicates impairment of reverse cholesterol pathwayEffects of aerobic exercise on lipids and lipoproteinsObesity, hypertension, and vascular disease.Prediction of risk factors for coronary heart disease using Framingham Risk Score in Korean men.Both serum apolipoprotein B and the apolipoprotein B/apolipoprotein A-I ratio are associated with carotid intima-media thicknessApolipoprotein B is highly associated with the risk of coronary heart disease as estimated by the Framingham risk score in healthy Korean men.Erythrocyte-bound apolipoprotein B in relation to atherosclerosis, serum lipids and ABO blood group.Use of lipoprotein particle measures for assessing coronary heart disease risk post-American Heart Association/American College of Cardiology guidelines: the Multi-Ethnic Study of Atherosclerosis.Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple- reaction-monitoring mass spectrometryIntegrated role of two apoliprotein E polymorphisms on apolipoprotein B levels and coronary artery disease in a biethnic population.Comparison of efficacy of intensive versus mild pitavastatin therapy on lipid and inflammation biomarkers in hypertensive patients with dyslipidemia.Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy.Apolipoprotein B Is Related to Metabolic Syndrome Independently of Low Density Lipoprotein Cholesterol in Patients with Type 2 Diabetes.Compendium of genome-wide scans of lipid-related phenotypes: adding a new genome-wide search of apolipoprotein levels.Pathogenesis and management of diabetic dyslipidemia.Non-high-density lipoprotein cholesterol: why lower is better.Reference intervals for serum total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, Lp (a), apolipoprotein A-I, A-II, B, C-II, C-III, and E in healthy South Indians from Andhra Pradesh.Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samplesApo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.Apolipoproteins AI and B as therapeutic targets.Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies.The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence.Apolipoprotein A-I and risk for cardiovascular diseases.Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.Metabolic alterations and systemic inflammation in obstructive sleep apnea among nonobese and obese prepubertal children.Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles.The evolving definitions and increasing prevalence of the metabolic syndrome.The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment.A study of serum apolipoprotein A1, apolipoprotein B and lipid profile in stroke.Genetic polymorphisms for the study of multifactorial stroke.Genetic disruption of myostatin reduces the development of proatherogenic dyslipidemia and atherogenic lesions in Ldlr null miceAbdominal obesity: the cholesterol of the 21st century?Serum lipid profile constituents as markers of cardiovascular morbidity in patients on chronic hemodialysis.A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias.Biomarkers related to aging in human populations.Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population.Metabolic consequences of sleep-disordered breathing.Discrimination of ischemic and hemorrhagic strokes using a multiplexed, mass spectrometry-based assay for serum apolipoproteins coupled to multi-marker ROC algorithmApolipoprotein measurements: is more widespread use clinically indicated?
P2860
Q28351795-FD8F76DB-5AAE-416D-906C-BE902819AB43Q28397909-86D3E00B-65E5-451F-B34E-0F72DE4C5D56Q33876773-89854E70-46EB-4A04-BEC1-E7BC1FB0DCE6Q34028181-9C62E820-4F58-45B6-9E2B-8B3DA84461D8Q34427908-476F2A69-0890-4EB4-8939-0E84F9063E37Q34566524-CED0AAF7-973D-4E55-AE61-4098018EFE89Q34853434-74067B3C-626C-40E2-8925-C6E9A0E901C2Q34999677-00CE0CFD-943D-4C5A-9F99-D6976B30C865Q35007779-BCBF854D-0890-438F-BC2E-F92FAF97FCE4Q35012598-DDEE01C6-8947-4832-9E0F-F1798D49DB3CQ35075040-925F9293-E00E-4675-982E-0455EAF61643Q35106600-6F7E3D38-2B61-46F1-973F-2F35DDD5AF09Q35640331-D6592E99-E798-4E88-A128-D883270F1982Q35868249-74746607-ECAF-4655-B84A-1060FAEFF2CFQ35890892-B4BEB819-74A7-4AB7-ABE1-DED12694B635Q36168178-2E93B31F-C24F-4D23-B0AE-AFB8B7FAF11CQ36202132-4B146FAD-2328-45C3-AC3B-A08ADD76B037Q36262966-17DA755B-23B9-4E65-A677-E492B92DEC9EQ36318265-B593BF7C-1CD4-4659-B1BF-D99E759F29D6Q36395720-759FDA88-7D7D-4B44-A7AE-8BB7BB74D39CQ36455892-DD4E2FBB-9D59-45B3-AC53-EAF58A484233Q36455898-E09443BB-1547-40DD-A788-F4E7EC78CB01Q36455901-5AE8E319-EE08-4E90-84BE-BBC80D6988A8Q36562244-21ED8C46-9A12-425B-865B-C6F687BC6C40Q36593266-5FC3DC6E-D4E6-46E1-9C0D-793FD47BE9BAQ36657681-5E53FD62-1B20-40AB-9862-4D5FD9D97DD5Q36675450-66085F12-D31B-466D-86CB-B163622F9304Q36749236-08BB2582-71CF-4110-BE2F-FADF4025120FQ37107485-01BEEC6C-D85B-4C1D-814A-04ABCF2FD092Q37111281-0CC834B6-A6AF-433A-A1B3-4830AF7ED618Q37141815-57AC5623-567B-423A-9341-68FBE219FEF7Q37267076-D9B18AAD-F4DF-4376-A0CE-21E850F9351AQ37267248-5D4411AA-9EC1-420F-91D0-EAD312E36A49Q37277947-93357F3D-D646-42C9-86C3-E396797CE0F5Q37288388-33D8A649-ED8E-461C-A810-08296FC01224Q37323794-D1D0D19A-44F9-48AA-B5C5-CC685CC6F703Q37441909-8F88264D-3692-4DF4-ACD6-B37553F7A7D2Q37511434-67914E02-22B5-4F87-8ACF-B0EE7E04FDEAQ37542168-BA31A67D-0512-48AD-8D44-EA7DE78BADB6Q37594701-62AAF39F-74FE-4072-AD3D-1B5A7A1CE656
P2860
Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Apolipoprotein A-I and B level ...... e Québec cardiovascular study.
@en
type
label
Apolipoprotein A-I and B level ...... e Québec cardiovascular study.
@en
prefLabel
Apolipoprotein A-I and B level ...... e Québec cardiovascular study.
@en
P2093
P356
P1433
P1476
Apolipoprotein A-I and B level ...... e Québec cardiovascular study.
@en
P2093
Bernard PM
Dagenais GR
Després JP
Lamarche B
Moorjani S
P304
P356
10.1161/01.CIR.94.3.273
P407
P577
1996-08-01T00:00:00Z